Genotyping mice at 55% EBITDA - Acquisitions Anonymous 272
Genotyping mice at 55% EBITDA - Acquisitions Anonymous 272
In this episode of Acquisitions Anonymous, Michael and Heather discuss an investment opportunity in a genomic testing , specializing in...
Let us know if you enjoyed this episodeIn this episode of Acquisitions Anonymous, Michael and Heather discuss an investment opportunity in a genomic testing , specializing in DNA sequencing and genotyping for mice. Despite their initial unfamiliarity with the technical details, they recognize the company's significant role in pharmaceutical research. They are impressed by its financial performance, noting substantial growth in revenue and EBITDA, along with high margins. The conversation also...
Episode Transcript
More Episodes
$5M Mobility Business: Solid Franchise or Aging Market Risk?
A profitable multi-location mobility solutions franchise is under the microscope in this episode, with the team digging into payer mix, growth potential, and the real value of a franchise model.
Would You Pay $16M for a Crypto News Site?
In this episode, the hosts dissect a $16M listing for a crypto news media company claiming $6M in revenue—raising serious questions about valuation, legitimacy, and what the business actually does.
Inside a $26M Industrial Inspection Device Company
A $12M revenue, $3.8M EBITDA “Project Lucid” branded inspection device distributor sparks heated debate on IP risk, exclusivity with its manufacturer, and the eyebrow-raising $5M liquid funds buyer requirement.